EUCTR2020-001614-38-BE进行中（未招募）1 期
Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19 DAWN AZITHRO
ZLeuven0 个研究点目标入组 282 人开始时间: 2020年4月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 282
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject (=18 years old) or legally authorized representative provides informed consent prior to initiation of any study procedures. When signed informed consent is not possible (e.g. due to restrictions to prevent viral transmission), verbal informed consent in the presence of a witness not related to the investigational research study will be obtained.
- •2.Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
- •3.Male or non-pregnant female adult =18 years of age at time of enrolment.
- •4.Has a confirmed diagnosis of SARS-CoV-2 infection within 72 hours prior to randomization, defined as either:
- •a. laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen or
- •b. The combination of upper or lower respiratory infection symptoms (fever, cough, dyspnea, desaturation) and typical findings on chest CT scan and absence of other plausible diagnoses
- •5.Illness of any duration, and at least one of the following:
- •a.Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or
- •b.Clinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, or
- •c.Requiring mechanical ventilation and/or supplemental oxygen.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 141
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 141
排除标准
- •1. ALT/AST > 5 times the upper limit of normal.
- •2. Pregnancy or breast feeding.
- •3. Allergy to any study medication
- •4. Any medical condition which would impose an unacceptable safety hazard by participation to the study.
- •5. Study drug specific exclusion criteria:
- •*for Azithromycin :
- •oheart failure with severely reduced ejection fraction (30%)
- •oknown prolonged long QT interval on ECG (> 470 msec males and > 480 females with Fridericia criteria; for patients with ventricular conduction delay the use of Rautaharju formula is also allowed )
- •opatients on Macrolides during the last week before admission
- •*For other treatment strata, see arm-specific protocols.
研究者
相似试验
进行中（未招募）
1 期
COVID-19- Study conducted in more than 1 site, randomized, to evaluate the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf®) in hospitalized patients affected by SARS-COV-19 acute respiratory distress syndrome (ARDS)Hospitalized patients with SARS-COV-19 acute respiratory distress syndrome (ARDS)MedDRA version: 21.1Level: PTClassification code 10001052Term: Acute respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-002632-75-ITCHIESI FARMACEUTICI S.P.A.70
Unknown
3 期
A clinical trial to study the effects of several commercially available drugs in patients with mild COVID-19.CTRI/2022/01/039235Drugs for Neglected Diseases Initiative DNDi
招募中
3 期
An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19COVID 19PACTR202006537901307Drug for Neglected Diseases initiative3,000
尚未招募
3 期
Clinical trial of Tablet shatavari in stress managementCTRI/2023/07/055251Dr Pratik M Patil
进行中（未招募）
不适用
An open-label, controlled, randomized, prospective, between groups, multicenter clinical trial on the efficacy and safety of Fitostimoline (vaginal cream, vaginal suppositories and vaginal solution) and of Tantum Rosa (vaginal cream and vaginal solution) in the treatment of the vaginosis (non specific vaginitis) - NDEUCTR2008-005007-26-ITFARMACEUTICI DAMOR